Automated Author ProfileShrestha, J.
Shrestha, J.
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 0.5 (sum of 2 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
Pharmacogenomics (PGx) is increasingly being recognized as a potential tool for improving the efficacy and safety of drug therapy. Therefore, several efforts have been undertaken globally to facilitate the implementation process of PGx into routine clinical practice. Part of these efforts include the formation of PGx working groups working on PGx research, synthesis, and dissemination of PGx data and creation of PGx implementation strategies. In Asia, the Southeast Asian Pharmacogenomics Research Network (SEAPharm) is established to enable and strengthen PGx research among the various PGx communities within but not limited to countries in SEA; with the ultimate goal to support PGx implementation in the region. From the perspective of SEAPharm member countries, there are several key elements essential for PGx implementation at the national level. They include pharmacovigilance database, PGx research, health economics research, dedicated laboratory to support PGx testing for both research and clinical use, structured PGx education, and supportive national health policy. The status of these essential elements is presented here to provide a broad picture of the readiness for PGx implementation among the SEAPharm member countries, and to strengthen the PGx research network and practice in this region.
Authors
- Chumnumwat, S. ;
- Lu, Z.H. ;
- Sukasem, C. ;
- Winther, M.D. ;
- Capule, F.R. ;
- AbdulHamid, A.A. ;
- Bhandari, B. ;
- Chaikledkaew, U. ;
- Chanhom, N. ;
- Chantarangsu, S. ;
- Charoenyingwattana, A. ;
- Hang, T.T. ;
- Hlaing, T.M. ;
- Htun, K.S. ;
- Jittikoon, J. ;
- Le, L. ;
- Mahasirimongkol, S. ;
- MohamedNoor, D.A. ;
- Shrestha, J. ;
- Suwannoi, L. ;
- Tragulpiankit, P. ;
- Turongkaravee, S. ;
- Wattanapokayakit, S. ;
- Xangsayarath, P. ;
- Yuliwulandari, R. ;
- Zain, S.M. ;
- Chantratita, W.
Pharmacogenomics (PGx) is increasingly being recognized as a potential tool for improving the efficacy and safety of drug therapy. Therefore, several efforts have been undertaken globally to facilitate the implementation process of PGx into routine clinical practice. Part of these efforts include the formation of PGx working groups working on PGx research, synthesis, and dissemination of PGx data and creation of PGx implementation strategies. In Asia, the Southeast Asian Pharmacogenomics Research Network (SEAPharm) is established to enable and strengthen PGx research among the various PGx communities within but not limited to countries in SEA; with the ultimate goal to support PGx implementation in the region. From the perspective of SEAPharm member countries, there are several key elements essential for PGx implementation at the national level. They include pharmacovigilance database, PGx research, health economics research, dedicated laboratory to support PGx testing for both research and clinical use, structured PGx education, and supportive national health policy. The status of these essential elements is presented here to provide a broad picture of the readiness for PGx implementation among the SEAPharm member countries, and to strengthen the PGx research network and practice in this region.
Authors
- Chumnumwat, S. ;
- Lu, Z.H. ;
- Sukasem, C. ;
- Winther, M.D. ;
- Capule, F.R. ;
- AbdulHamid, A.A. ;
- Bhandari, B. ;
- Chaikledkaew, U. ;
- Chanhom, N. ;
- Chantarangsu, S. ;
- Charoenyingwattana, A. ;
- Hang, T.T. ;
- Hlaing, T.M. ;
- Htun, K.S. ;
- Jittikoon, J. ;
- Le, L. ;
- Mahasirimongkol, S. ;
- MohamedNoor, D.A. ;
- Shrestha, J. ;
- Suwannoi, L. ;
- Tragulpiankit, P. ;
- Turongkaravee, S. ;
- Wattanapokayakit, S. ;
- Xangsayarath, P. ;
- Yuliwulandari, R. ;
- Zain, S.M. ;
- Chantratita, W.